Private Advisor Group LLC acquired a new position in shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 55,777 shares of the company’s stock, valued at approximately $3,017,000. Private Advisor Group LLC owned 0.91% of SPDR S&P Pharmaceuticals ETF as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the business. LPL Financial LLC lifted its holdings in shares of SPDR S&P Pharmaceuticals ETF by 13.2% in the 4th quarter. LPL Financial LLC now owns 207,649 shares of the company’s stock worth $11,630,000 after purchasing an additional 24,252 shares during the last quarter. Wells Fargo & Company MN increased its position in SPDR S&P Pharmaceuticals ETF by 175.6% in the fourth quarter. Wells Fargo & Company MN now owns 207,229 shares of the company’s stock worth $11,607,000 after buying an additional 132,037 shares during the period. First Citizens Bank & Trust Co. lifted its stake in SPDR S&P Pharmaceuticals ETF by 2.5% in the fourth quarter. First Citizens Bank & Trust Co. now owns 186,004 shares of the company’s stock valued at $10,418,000 after buying an additional 4,575 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in SPDR S&P Pharmaceuticals ETF by 2.0% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 175,309 shares of the company’s stock valued at $9,819,000 after buying an additional 3,379 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in SPDR S&P Pharmaceuticals ETF by 96.9% in the first quarter. Goldman Sachs Group Inc. now owns 119,929 shares of the company’s stock valued at $5,253,000 after buying an additional 59,007 shares during the last quarter.
SPDR S&P Pharmaceuticals ETF Stock Performance
SPDR S&P Pharmaceuticals ETF stock opened at $70.05 on Friday. The firm has a market capitalization of $458.83 million, a P/E ratio of 14.28 and a beta of 0.58. The company has a 50-day simple moving average of $60.61 and a 200-day simple moving average of $57.66. SPDR S&P Pharmaceuticals ETF has a one year low of $40.80 and a one year high of $70.15.
SPDR S&P Pharmaceuticals ETF Profile
SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Articles
- Five stocks we like better than SPDR S&P Pharmaceuticals ETF
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Want to see what other hedge funds are holding XPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report).
Receive News & Ratings for SPDR S&P Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
